TAK · NYSE
TAK · NYSE
20.92 USD
+0.91 (+4.53%)
Takeda climbed 3.7% premarket after reporting fiscal second-quarter results above expectations and lifting its full-year profit guidance. Reuters earnings summary Earnings transcript The results highlighted higher revenue at reported exchange rates, transformation savings, launch momentum, and pipeline progress. FY2026 results Other large pharmaceutical stocks also rose, adding a smaller sector tailwind.
Takeda climbed 3.7% premarket after reporting fiscal second-quarter results above expectations and lifting its full-year profit guidance. Reuters earnings summary Earnings transcript The results highlighted higher revenue at reported exchange rates, transformation savings, launch momentum, and pipeline progress. FY2026 results Other large pharmaceutical stocks also rose, adding a smaller sector tailwind.